Hall S L, Murphy B R, van Wyke Coelingh K L
Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Vaccine. 1991 Sep;9(9):659-67. doi: 10.1016/0264-410x(91)90192-9.
The antigenicity, immunogenicity and efficacy of the human PIV3 fusion (F) glycoprotein expressed in insect cells by a baculovirus vector were studied. The results indicate that the PIV3 F glycoprotein expressed by a recombinant baculovirus is antigenically authentic as determined using a panel of PIV3 F specific monoclonal antibodies. Only a low level of antibody was stimulated by immunization of animals with infected cells, but the antibody appeared to be of high quality. Immunized animals were also moderately protected against PIV3 challenge. These results indicate that the baculovirus expression system is a reasonable source of authentic PIV3 F protein for use in a subunit vaccine.
研究了杆状病毒载体在昆虫细胞中表达的人副流感病毒3型（PIV3）融合（F）糖蛋白的抗原性、免疫原性和效力。结果表明，使用一组PIV3 F特异性单克隆抗体测定，重组杆状病毒表达的PIV3 F糖蛋白在抗原性上是真实的。用感染细胞免疫动物仅刺激产生低水平抗体，但该抗体似乎质量较高。免疫动物对PIV3攻击也有一定程度的保护作用。这些结果表明，杆状病毒表达系统是用于亚单位疫苗的真实PIV3 F蛋白的合理来源。
